The International Federation of Psoriasis Associations (IFPA) is a nonprofit organization uniting national and regional psoriasis associations from around the world. Since being founded in 1971, they have worked to resolve the international psoriasis community’s challenges. IFPA campaigns on behalf of all people with psoriasis and psoriatic arthritis. Their goals are to empower their members, improve living conditions for patients, raise awareness of psoriasis and psoriatic arthritis, and cooperate with fellow stakeholders.
The IPC and IFPA are currently working together on:
– Global Psoriasis Atlas (GPA)
– Recategorization of disease severity
– Skin of Color
The National Psoriasis Foundation (NPF) is a nonprofit organization in the United States dedicated to finding a cure for psoriasis and psoriatic arthritis. It serves as a resource for individuals affected by these conditions, providing support, education, and advocacy. The NPF conducts research, raises awareness, and works to improve access to effective treatments and healthcare for people living with psoriasis and psoriatic arthritis.
Officially founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health around the world for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology. Today, the ILDS represents dermatology at the highest level, with over 180 Member Societies from more than 80 countries, representing over 200,000 dermatologists. ILDS works closely with partners worldwide, including the World Health Organization (WHO), with whom ILDS is in official relations, to improve skin health for all people.
PsoProtect is an international registry for health care providers to report outcomes of COVID-19 in individuals with psoriasis. The information provided informs clinicians when assessing risk and treating COVID-19 in patients with psoriasis and other immune-mediated inflammatory diseases. It will help improve the understanding of how factors such as immunomodulator therapies and comorbidities affect outcomes of COVID-19 in psoriasis. PsoProtect provides regular, open access summaries of all reported cases in PsoProtect, for the benefit of the international psoriasis community.
Founded in July 2008 in Buenos Aires, Argentina, SOLAPSO emerged as a visionary endeavor spearheaded by seasoned dermatologists passionate about advancing the understanding, diagnosis, and treatment of psoriasis. Their shared commitment to fostering the growth and dissemination of knowledge surrounding this condition in Latin America led to its official establishment as a civil association in November of the same year. Since then, SOLAPSO has played a pivotal role in promoting regional awareness through impactful events across various countries and valuable support for scientific publications, amplifying the knowledge surrounding psoriasis in Latin America.
The Psoriasis and Psoriatic Arthritis Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in psoriasis and psoriatic arthritis. Our aim is to enhance knowledge on psoriasis and psoriatic arthritis through the multichannel dissemination of global advances related to classification, diagnosis, treatment, and management.
The Psoriasis and Psoriatic Arthritis Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
Get in Touch With IPC